Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for biotechnology industry professionals · Friday, December 14, 2018 · 471,116,103 Articles · 3+ Million Readers

UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence

- Event will be webcast live -

/EIN News/ -- SAN FRANCISCO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it will host an Investor & Analyst Event on Cellular Senescence on Tuesday, December 11, 2018 from 9:00 a.m. – 11:30 a.m. ET in New York, NY.

Leading experts will discuss the biology of cellular senescence and its relationship to aging and diseases associated with aging. UNITY leadership will also review the company’s approach to extending healthspan through the creation of senolytic medicines.

The event will feature presentations from the following experts in the field of cellular senescence:

  • Judith Campisi, Ph.D. – Professor at the Buck Institute for Research on Aging; Senior Scientist at Lawrence Berkeley National Laboratory; National Academy of Sciences member
  • Jan van Deursen, Ph.D. – Professor of Biochemistry and Molecular Biology at The Mayo Clinic; Professor of Pediatrics at The Mayo Clinic

A live webcast will be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event. Pre-registration is required to attend in person. Institutional investors and analysts interested in attending the event in New York City can email ir@unitybiotechnology.com to receive additional information.

About UNITY
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

Investors
                    Endurance Advisors
                    Elizabeth Broder
                    ebroder@enduranceadvisors.com
                    
                    Media
                    Austine Graff
                    707-593-6151
                    austine.graff@unitybiotechnology.com

UNITY color transp BG.jpg

Powered by EIN News
Distribution channels:


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release